BLASINGLE-USEVIALPriority Review
Approved
Nov 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
TYSABRI (natalizumab) by Biogen is integrin receptor antagonists [moa]. Approved for multiple sclerosis, relapsing-remitting, crohn's disease. First approved in 2004.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TYSABRI (natalizumab) is a monoclonal antibody integrin receptor antagonist approved by the FDA in November 2004. It is administered as a single-use intravenous infusion and works by blocking integrin receptors to prevent immune cells from crossing the blood-brain barrier. While specific indications are not detailed in the provided data, natalizumab is primarily indicated for multiple sclerosis and Crohn's disease. The product represents an important therapeutic option in the immunosuppression and neurology treatment landscape.
$0.0BPart D
Mechanism of Action
Integrin Receptor Antagonists
Pharmacologic Class:
Integrin Receptor Antagonist
Worked on TYSABRI at Biogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.